Skip to main content

Silk Road Medical Announces Changes to Board of Directors

Written by Customer Service on . Posted in Public Companies.

SUNNYVALE, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of Kevin Ballinger to the company’s Board of Directors. Simultaneously, the company also announced the resignation of current board member, Ruoxi Chen. Both of these changes are effective immediately.
Ballinger, the recently appointed Chief Executive Officer of Aldevron, brings decades of experience in the medical device industry. Prior to joining Aldevron, he spent 25 years at Boston Scientific, a company focused on a variety of interventional medical specialties. During his last nine years at Boston Scientific, he served as Executive Vice President and Global President of the Interventional Cardiology division. Under his leadership, Ballinger grew the division to a $3 billion global business. Ballinger earned his BS in Mechanical Engineering from Michigan Technological University, and his MBA from the University of Minnesota’s Carlson School of Management.“We are delighted to welcome Kevin to our Board of Directors. Kevin brings extensive strategic leadership experience in the medical device industry, with a proven track record of successfully building and growing businesses,” said Erica Rogers, Chief Executive Officer. “His guidance will be instrumental as we look toward significant growth and operational expansion at Silk Road Medical.”“Silk Road Medical has established itself as a leader in the treatment of carotid artery disease with its revolutionary transcarotid access and neuroprotection products,” said Ballinger. “I am excited about the future prospects of the company and look forward to working together as we continue to build a world class organization. I am thrilled to be joining such a dedicated team that is at the forefront of innovation.”About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.Investors:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.comMedia:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.